Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2022-06-30), NovoCure's Intrinsic Value: Projected FCF is $2.79. The stock price of NovoCure is $69.50. Therefore, NovoCure's Price-to-Intrinsic-Value-Projected-FCF of today is 24.9.
The historical rank and industry rank for NovoCure's Intrinsic Value: Projected FCF or its related term are showing as below:
NVCR'
s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 24.94 Med: 54.07 Max: 568.77
Current: 24.91
During the past 9 years, the highest Price-to-Intrinsic-Value-Projected-FCF of NovoCure was 568.77. The lowest was 24.94. And the median was 54.07.
NVCR's Price-to-Intrinsic-Value-Projected-FCF is ranked worse than 99.07% of 322
companies
in the Medical Devices & Instruments industry
Industry Median: 1.78
vs NVCR: 24.91
NovoCure Intrinsic Value: Projected FCF Historical Data
The historical data trend for NovoCure's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
NovoCure Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Intrinsic Value: Projected FCF
-
-
-
-0.91
2.14
NovoCure Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Intrinsic Value: Projected FCF
-1.05
0.39
1.59
2.14
2.79
Competitive Comparison
For the Medical Instruments & Supplies subindustry, NovoCure's Intrinsic Value: Projected FCF, along with its competitors' market caps and Intrinsic Value: Projected FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure Intrinsic Value: Projected FCF Distribution
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Intrinsic Value: Projected FCF distribution charts can be found below:
* The bar in red indicates where NovoCure's Intrinsic Value: Projected FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
NovoCure's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
69.50
/
2.7943564983447
=
24.87
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NovoCure Intrinsic Value: Projected FCF Related Terms
Thank you for viewing the detailed overview of NovoCure's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
2.9(4.01%) Volume: 512,097 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:NVCR has been successfully added to your 
